特发性肺动脉高压患者血清高迁移率族蛋白B1水平及其临床意义  

Serum HMGB1 Levels and Its Clinical Significance in Patients with Idiopathic Pulmonary Arterial Hypertension

作　　者：罗俊[1] 苏威 朱腾腾 王懿 盛斌[1] 熊贤良 泰瑞斯 李江[1] 

机构地区：[1]中南大学湘雅二医院心内科,湖南长沙410011 [2]南方医科大学附属第三医院心内科,广东广州510515

出　　处：《中山大学学报（医学科学版）》2017年第6期860-865,共6页Journal of Sun Yat-Sen University:Medical Sciences

基　　金：国家自然科学基金(81370249;81600249);湖南省自然科学基金(2017JJ3455)

摘　　要：【目的】探讨血清高迁移率组蛋白B1(HMGB1)作为特发性肺动脉高压(IPAH)患者生物标志物的可行性及临床价值。【方法】收集2011年5月至2015年4月中南大学湘雅二医院住院及门诊的IPAH患者33例,并对8例使用肺动脉高压靶向药物治疗的IPAH患者随访6个月。采用酶联免疫法(ELISA)测定血清HMGB1浓度。【结果】IPAH患者血清HMGB1水平(ng/m L)显著高于健康成人对照组(14.8±2.4 vs.3.8±1.2,P<0.001)。IPAH患者血清HMGB1水平与平均肺动脉压力、肺血管阻力呈显著正相关(r=0.460,P=0.002;r=0.541,P=0.001)。8例IPAH患者使用肺动脉高压靶向药物治疗6月后,在肺动脉压力(mm Hg,62.3±9.7 vs.54.0±8.7,P<0.001)和6 min步行试验(m)得到改善的同时(368±69 vs 401±55,P<0.001),血清HMGB1水平(ng/m L)显著降低(15.9±5.3 vs.11.1±2.5,P=0.021)。【结论】检测血清HMGB1水平可在一定程度上反映肺动脉高压靶向药物的治疗效果,有望成为IPAH患者重要的随访指标。【Objective】To estimate the clinical value of serum high mobility group box 1(HMGB1) as a biomarker of idiopathic pulmonary arterial hypertension(IPAH).【Methods】This study included 33 patients with IPAH that were confirmed by right heart catheter in the Second Xiangya Hospital, Central South University from May 2011 to April 2015. 8 patients with IPAH were followed up for 6 months during treating with PAH-specific pharmacotherapies. All the subjects clinical data were collected,HMGB1 levels were determined by enzyme linked immunosorbent assay(ELISA).【Results】Serum HMGB1 levels(ng/m L) were significantly increased in patients with IPAH compared with the control group(14.8 ± 2.4 vs. 3.8 ± 1.2, P<0.001); The serum HMGB1 levels were significantly positive correlation with mean pulmonary arterial pressure(MPAP) and pulmonary vascular resistauce(PVR)(r=0.864, P<0.001; r=0.460,P=0.002) in the patients with IPAH. After treating with PAH-specific pharmacotherapies for 6 month, HMGB1 levels(ng/m L)were significantly decreased(15.9±5.3 vs 11.1±2.5,P=0.021)along with the patients' MPAP(62.3±9.7 vs 54.0±8.7,mm Hg)and 6-min walk distances(m)improved(368±69 vs 401±55,P<0.001).【Conclusions】Our study suggested that serum HMGB1 may be used as a biomarker of treatment response to targeted therapy, and it will be used as a biomarker in the follow-up evaluation of patients with IPAH.

关 键 词：特发性肺动脉高压 高迁移率族蛋白B1 艾森曼格综合征 靶向药物 

分 类 号：R45[医药卫生—治疗学]